» Articles » PMID: 37096787

Latent Heterogeneity of Muscle-invasive Bladder Cancer in Patient Characteristics and Survival: A Population-based Nation-wide Study in the Bladder Cancer Data Base Sweden (BladderBaSe)

Overview
Journal Cancer Med
Specialty Oncology
Date 2023 Apr 25
PMID 37096787
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with muscle-invasive bladder cancer (MIBC) constitute a heterogenous group in terms of patient and tumour characteristics ('case-mix') and prognosis. The aim of the current study was to investigate whether differences in survival could be used to separate MIBC patients into separate classes using a recently developed latent class regression method for survival analysis with competing risks.

Methods: We selected all participants diagnosed with MIBC in the Bladder Cancer Data Base Sweden (BladderBase) and analysed inter-patient heterogeneity in risk of death from bladder cancer and other causes.

Results: Using data from 9653 MIBC patients, we detected heterogeneity with six distinct latent classes in the studied population. The largest, and most frail class included 50% of the study population and was characterised by a somewhat larger proportion of women, higher age at diagnosis, more advanced disease and lower probability of curative treatment. Despite this, patients in this class treated with curative intent by radical cystectomy or radiotherapy had a lower association to risk of death. The second largest class included 23% and was substantially less frail as compared to the largest class. The third and fourth class included each around 9%-10%, whereas the fifth and sixth class included each 3%-4% of the population.

Conclusions: Results from the current study are compatible with previous research and the method can be used to adjust comparisons in prognosis between MIBC populations for influential differences in the distribution of sub-classes.

Citing Articles

Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics and survival: A population-based nation-wide study in the Bladder Cancer Data Base Sweden (BladderBaSe).

Haggstrom C, Rowley M, Liedberg F, Coolen A, Holmberg L Cancer Med. 2023; 12(12):13856-13864.

PMID: 37096787 PMC: 10315802. DOI: 10.1002/cam4.5981.

References
1.
de Jong J, Boormans J, van Rhijn B, Seiler R, Boorjian S, Konety B . Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol. 2020; 3(4):420-423. DOI: 10.1016/j.euo.2020.02.010. View

2.
Chappidi M, Kates M, Patel H, Tosoian J, Kaye D, Sopko N . Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. Urol Oncol. 2016; 34(6):256.e1-6. PMC: 4875870. DOI: 10.1016/j.urolonc.2015.12.010. View

3.
Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M . Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011; 185(3):833-9. DOI: 10.1016/j.juro.2010.10.061. View

4.
Russell B, Liedberg F, Khan M, Nair R, Thurairaja R, Malde S . A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. Eur Urol Oncol. 2019; 3(2):239-249. DOI: 10.1016/j.euo.2019.09.008. View

5.
Gray P, Fedewa S, Shipley W, Efstathiou J, Lin C, Zietman A . Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2012; 63(5):823-9. DOI: 10.1016/j.eururo.2012.11.015. View